Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells
about
Eribulin in Cancer TreatmentPhase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistanceIn vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabPrognostic Value of EMT-inducing Transcription Factors (EMT-TFs) in Metastatic Breast Cancer: A Systematic Review and Meta-analysis.Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective.Review on the clinical use of eribulin mesylate for the treatment of breast cancer.Eribulin in non-small cell lung cancer: challenges and potential strategies.Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.High-level expression of ARID1A predicts a favourable outcome in triple-negative breast cancer patients receiving paclitaxel-based chemotherapy.OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition.Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy
P2860
Q26799328-A7B0B52C-54FF-4DB8-A448-A98B517875FBQ36922483-DB14F4FF-713B-4219-BE0D-46D83FE223EAQ36964337-7A24CCDF-8773-4FB8-8E96-F806FB58A4A9Q37030764-30459EE6-6D32-4569-9800-4DD7F65EAFF8Q37419295-C23833C9-CCBC-4CDD-B952-DBCAD75617D8Q38432883-F24D1D9A-98C4-4352-87EE-C1285B6A5983Q38711371-2D41D0EB-0311-45E1-9AE0-5C4F6C9651B5Q39120142-CC78E2BB-BF3F-44AB-A850-14C69D50800DQ47131131-6762CCB6-44A4-4F8A-927D-F2963D330E55Q48116981-A4B1D226-26F6-4E4A-B2A9-FD965196B1C6Q49489812-B0D4C56B-B1AE-4A76-8FCE-42EC453C6664Q49787954-D869C46B-4004-4370-9F6F-FDC4DCE25368Q54978314-2C324004-7CDC-4BCB-9278-D15C5DBE9117Q55449946-C8D89FCF-3158-427F-93D5-AAEA3C11AFF3Q57577429-B6720C9E-121A-40E3-91BD-2E63784636F3
P2860
Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gene expression profiling reve ...... sensitive breast cancer cells
@ast
Gene expression profiling reve ...... sensitive breast cancer cells
@en
Gene expression profiling reve ...... sensitive breast cancer cells
@nl
type
label
Gene expression profiling reve ...... sensitive breast cancer cells
@ast
Gene expression profiling reve ...... sensitive breast cancer cells
@en
Gene expression profiling reve ...... sensitive breast cancer cells
@nl
prefLabel
Gene expression profiling reve ...... sensitive breast cancer cells
@ast
Gene expression profiling reve ...... sensitive breast cancer cells
@en
Gene expression profiling reve ...... sensitive breast cancer cells
@nl
P2093
P2860
P3181
P1433
P1476
Gene expression profiling reve ...... sensitive breast cancer cells
@en
P2093
Amy Weaver
Jesse Chow
Judith Oestreicher
Sergei Agoulnik
Stephanie Santiago
Yasuhiro Funahashi
Yoshiya Oda
Zoltán Dezső
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0106131
P407
P577
2014-01-01T00:00:00Z